The combination of DSF, which reduces the protumor activity of macrophages, can significantly increase the number of cytotoxic CD8+ T cells in tumor cells when combined with PD-1 antibodies, enhancing the antitumor immune response and synergistically inhibiting the growth and metastasis of tumor cells. The gene discussed is CD8A; the disease is neoplasm.